JP2010501010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501010A5 JP2010501010A5 JP2009524806A JP2009524806A JP2010501010A5 JP 2010501010 A5 JP2010501010 A5 JP 2010501010A5 JP 2009524806 A JP2009524806 A JP 2009524806A JP 2009524806 A JP2009524806 A JP 2009524806A JP 2010501010 A5 JP2010501010 A5 JP 2010501010A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- composition
- methyl
- use according
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 239000001257 hydrogen Substances 0.000 claims description 48
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 25
- -1 hydroxy, methyl Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 12
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 12
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229940123993 Incretin mimetic Drugs 0.000 claims description 9
- 108010011459 Exenatide Proteins 0.000 claims description 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 208000001280 Prediabetic State Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229960001519 exenatide Drugs 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims description 5
- 239000000859 incretin Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- AFENDNXGAFYKQO-GSVOUGTGSA-N (R)-2-hydroxybutyric acid Chemical compound CC[C@@H](O)C(O)=O AFENDNXGAFYKQO-GSVOUGTGSA-N 0.000 claims description 4
- GFGJCAMOIIXWCC-UHFFFAOYSA-N 2-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-n-hydroxyacetamide Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CC(=O)NO)=C1 GFGJCAMOIIXWCC-UHFFFAOYSA-N 0.000 claims description 4
- FIIULAILAPDPJC-UHFFFAOYSA-N 2-[3-[(2,6-dimethylphenyl)methoxy]phenyl]acetic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CC(O)=O)=C1 FIIULAILAPDPJC-UHFFFAOYSA-N 0.000 claims description 4
- FIMRNLAKAARHPD-IRXDYDNUSA-N 2-[4-[[2-[(2s,5r)-2-cyano-5-ethynylpyrrolidin-1-yl]-2-oxoethyl]amino]-4-methylpiperidin-1-yl]pyridine-4-carboxylic acid Chemical compound C1CC(C)(NCC(=O)N2[C@@H](CC[C@@H]2C#C)C#N)CCN1C1=CC(C(O)=O)=CC=N1 FIMRNLAKAARHPD-IRXDYDNUSA-N 0.000 claims description 4
- HFVDIZNJYLODRP-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCC(O)=O)=C1 HFVDIZNJYLODRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 208000003790 Foot Ulcer Diseases 0.000 claims description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 4
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 206010040943 Skin Ulcer Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 229960001667 alogliptin Drugs 0.000 claims description 4
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 4
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 229960002397 linagliptin Drugs 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229960004937 saxagliptin Drugs 0.000 claims description 4
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 4
- 108010033693 saxagliptin Proteins 0.000 claims description 4
- 229960004034 sitagliptin Drugs 0.000 claims description 4
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- 229960001254 vildagliptin Drugs 0.000 claims description 4
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 230000004596 appetite loss Effects 0.000 claims description 3
- 208000019017 loss of appetite Diseases 0.000 claims description 3
- 235000021266 loss of appetite Nutrition 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 23
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82267606P | 2006-08-17 | 2006-08-17 | |
| PCT/US2007/076116 WO2008022267A2 (en) | 2006-08-17 | 2007-08-16 | Combination treatment for metabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013008939A Division JP2013091662A (ja) | 2006-08-17 | 2013-01-22 | 代謝障害のための併用処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501010A JP2010501010A (ja) | 2010-01-14 |
| JP2010501010A5 true JP2010501010A5 (enExample) | 2011-09-08 |
Family
ID=39083142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524806A Pending JP2010501010A (ja) | 2006-08-17 | 2007-08-16 | 代謝障害のための併用処置 |
| JP2013008939A Pending JP2013091662A (ja) | 2006-08-17 | 2013-01-22 | 代謝障害のための併用処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013008939A Pending JP2013091662A (ja) | 2006-08-17 | 2013-01-22 | 代謝障害のための併用処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100227809A1 (enExample) |
| EP (1) | EP2056673A4 (enExample) |
| JP (2) | JP2010501010A (enExample) |
| KR (1) | KR20090038908A (enExample) |
| CN (1) | CN101505594A (enExample) |
| AU (1) | AU2007285827A1 (enExample) |
| CA (1) | CA2661293A1 (enExample) |
| IL (1) | IL197001A0 (enExample) |
| MX (1) | MX2009001763A (enExample) |
| NZ (1) | NZ574664A (enExample) |
| WO (1) | WO2008022267A2 (enExample) |
| ZA (1) | ZA200900734B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1868595B1 (en) | 2005-04-01 | 2012-01-11 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| CA2639939A1 (en) * | 2006-02-02 | 2007-08-16 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
| US8481595B2 (en) * | 2008-01-15 | 2013-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8829058B2 (en) * | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| TWI466672B (zh) * | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| CA2751834C (en) * | 2009-02-13 | 2018-07-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| EA022032B1 (ru) | 2009-09-30 | 2015-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения глюкопиранозилзамещенных производных бензилбензола |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| CA2782179C (en) | 2009-11-27 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| PT2566469T (pt) | 2010-05-05 | 2023-01-10 | Boehringer Ingelheim Int | Terapia de combinação |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| PL3517539T3 (pl) | 2011-07-15 | 2023-04-24 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2906115T3 (es) | 2013-04-18 | 2022-04-13 | Boehringer Ingelheim Int | Composición farmacéutica, métodos de tratamiento y usos de la misma |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| MX390363B (es) | 2016-06-10 | 2025-03-20 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina |
| MX2019005435A (es) | 2016-11-10 | 2019-07-10 | Boehringer Ingelheim Int | Composicion farmaceutica, metodos para tratamiento y sus usos. |
| KR20250172583A (ko) | 2023-03-14 | 2025-12-09 | 쑤저우 하이이 바이오메디컬 테크놀로지 씨오. 엘티디. | 1,4-폴리이소프렌 분산 시스템과 약물 활성 성분 및 그 응용 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629849B2 (en) * | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| US6723530B1 (en) * | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| RU2242244C2 (ru) * | 1999-01-14 | 2004-12-20 | Амилин Фармасьютикалз, Инк. | Новые композиции агонистов эксендина и способы их введения |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| ATE397938T1 (de) * | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
| CZ20033394A3 (cs) * | 2001-06-12 | 2005-03-16 | Wellstat Therapeutics Corporation | Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy |
| JP2006507303A (ja) * | 2002-11-01 | 2006-03-02 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| EP1569682A2 (en) * | 2002-12-03 | 2005-09-07 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
| PL377712A1 (pl) * | 2003-02-13 | 2006-02-06 | Wellstat Therapeutics Corporation | Związki do leczenia zaburzeń metabolicznych |
| MXPA05011042A (es) * | 2003-04-15 | 2005-12-15 | Wellstat Therapeutics Corp | Compuestos para el tratamieno de trastornos metabolicos. |
| CN100348186C (zh) * | 2003-04-30 | 2007-11-14 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| NZ597499A (en) * | 2004-05-14 | 2013-04-26 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| EP1868595B1 (en) * | 2005-04-01 | 2012-01-11 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| FR2887881B1 (fr) | 2005-07-01 | 2009-10-09 | Pierre Fabre Medicament Sa | Inhibiteurs de proteines kinases |
| EP1976378A4 (en) * | 2006-01-25 | 2010-06-09 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| WO2007087505A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2007
- 2007-08-16 CN CNA2007800303623A patent/CN101505594A/zh active Pending
- 2007-08-16 KR KR1020097003217A patent/KR20090038908A/ko not_active Ceased
- 2007-08-16 JP JP2009524806A patent/JP2010501010A/ja active Pending
- 2007-08-16 NZ NZ574664A patent/NZ574664A/en not_active IP Right Cessation
- 2007-08-16 MX MX2009001763A patent/MX2009001763A/es not_active Application Discontinuation
- 2007-08-16 WO PCT/US2007/076116 patent/WO2008022267A2/en not_active Ceased
- 2007-08-16 EP EP07841018A patent/EP2056673A4/en not_active Withdrawn
- 2007-08-16 AU AU2007285827A patent/AU2007285827A1/en not_active Abandoned
- 2007-08-16 US US12/377,460 patent/US20100227809A1/en not_active Abandoned
- 2007-08-16 CA CA002661293A patent/CA2661293A1/en not_active Abandoned
-
2009
- 2009-01-30 ZA ZA200900734A patent/ZA200900734B/xx unknown
- 2009-02-11 IL IL197001A patent/IL197001A0/en unknown
-
2013
- 2013-01-22 JP JP2013008939A patent/JP2013091662A/ja active Pending
- 2013-01-24 US US13/749,135 patent/US20130137629A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501010A5 (enExample) | ||
| US10077268B2 (en) | FXR agonists and methods for making and using | |
| JP2009528275A5 (enExample) | ||
| US20100227809A1 (en) | Combination treatment for metabolic disorders | |
| JP6391572B2 (ja) | 非アルコール性脂肪性肝疾患治療剤 | |
| CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
| US20180000768A1 (en) | Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions | |
| US20210221793A1 (en) | Pyrazole derivatives as sgc stimulators | |
| JP4643760B2 (ja) | Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| JP2017510572A (ja) | Ｆｘｒアゴニストならびに作製および使用のための方法 | |
| CN110312714B (zh) | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 | |
| JP2009532372A5 (enExample) | ||
| JP2010514828A5 (enExample) | ||
| CN103539791B (zh) | Gpr119 受体调节剂和对与其相关的障碍的治疗 | |
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2006524252A5 (enExample) | ||
| CA2521589A1 (en) | Compounds for the treatment of metabolic disorders | |
| KR20140003379A (ko) | 스핑고신 1-포스페이트(ｓ１ｐ) 수용체들에 대한 리간드들로서의 5-(바이페닐-4-일)-3-페닐-1,2,4-옥사디아졸릴 유도체들 | |
| JP2009524686A5 (enExample) | ||
| WO2021005436A1 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| JP2009539877A5 (enExample) | ||
| EP2668951B9 (en) | 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| WO2006132196A1 (ja) | β３作動薬を含有する新規な医薬 |